Differentiation of Isolated Small Bowel Crohn’s Disease from Other Small Bowel Ulcerative Diseases: Clinical Features and Double-Balloon Enteroscopy Characteristics

Meng Niu, Zheng-Hao Chen, Meng Li, Xing Zhang, and Chun-Xiao Chen

1Department of Gastroenterology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310003, China
2Department of Gastroenterology, Yiwu Fuyuan No. 1 Hospital, Yiwu, Zhejiang Province 322000, China
3Department of Internal Medicine, Dongtou District People’s Hospital, Wenzhou, Zhejiang Province 325000, China
4Department of Gastroenterology, Affiliated Hospital of Shaoxing University (Shaoxing Municipal Hospital), Shaoxing, Zhejiang Province 312000, China

Correspondence should be addressed to Chun-Xiao Chen; 13906523922@126.com

Received 23 December 2021; Accepted 4 May 2022; Published 30 May 2022

Academic Editor: Paul A. Rufo

Copyright © 2022 Meng Niu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The diagnosis of isolated small bowel Crohn’s disease (ISBCD) has always been challenging. Aims. This study is aimed at comparing the clinical features and double-balloon enteroscopy (DBE) characteristics of ISBCD with those of other small bowel ulcerative diseases (OSBUD). Methods. Patients with coexisting colonic and/or ileal valve lesions (n = 45) or whose final diagnosis was not determined (n = 29) were excluded. One hundred thirty-nine patients with ISBCD and 62 patients with OSBUD found by DBE were retrospectively analyzed. Results. The age of ISBCD onset was lower than that of OSBUD (OR 0.957, 95% CI 0.938-0.977, p < 0.001). Abdominal pain was more common in ISBCD (OR 4.986, 95% CI 2.539-9.792, p < 0.001). Elevated fibrinogen levels (OR 1.431, 95% CI 1.022-2.003, p = 0.037) and lower levels of D-dimer (OR 0.999, 95% CI 0.999-1.000, p = 0.017) were also more supportive of the diagnosis of ISBCD. Nonsteroidal anti-inflammatory drugs (NSAIDs) used for more than two weeks decreased the probability of a diagnosis of ISBCD (OR 0.173, 95% CI 0.043-0.695, p < 0.013). Abdominal computed tomography revealed a higher proportion of skip lesions in ISBCD than in OSBUD (OR 9.728, 95% CI 3.676-25.742, p < 0.001). The ulcers of ISBCD were more distributed in the ileum (111 (79.9%) vs. 29 (46.8%), p < 0.001), and their main morphology differed in different intestinal segments. Longitudinal ulcer (OR 14.293, 95% CI 4.920-41.518, p < 0.001) contributed to the differentiation of ISBCD from OSBUD. We constructed a diagnostic model, ISBCD index (AUROC = 0.877, 95% CI: 0.830-0.925), using multifactorial binary logistic regression to help distinguish between these two groups of diseases. Conclusion. Clinical features, laboratory tests, abdominal computed tomography, DBE characteristics, and pathology help to distinguish ISBCD from OSBUD.

1. Introduction

Crohn’s disease (CD) is a chronic, nonspecific inflammatory disease of unknown etiology that can affect the entire gastrointestinal tract [1]. According to previous reports, 30–70% of patients with CD have small bowel involvement, while up to 30% of patients diagnosed with CD have only small bowel involvement [2, 3]. Ulcers are the most common manifestation of small bowel CD [4, 5]. Additionally, other small bowel diseases (OSBUD), such as lymphoma, adenocarcinoma, diverticulum, tuberculosis, and Behcet’s disease, also present with various forms of small intestinal ulcers [6–13]. As a result, the diagnosis of isolated small bowel Crohn’s disease (ISBCD) has always been a challenge [14].

Due to the unique anatomical structure of the small intestine, it is difficult to provide an effective diagnosis for ISBCD with traditional methods, such as esophagogastrroduodenoscopy, colonoscopy, X-ray examination, and high-
resolution ultrasound. Computed tomography (CT) and magnetic resonance imaging have advantages in revealing transmural diseases and providing evidence of stenosis and fibrosis [15, 16]. However, lesions on the mucosal surface, such as ulcers and erosions, may be missed. Small bowel capsule endoscopy allows the direct visualization of the mucosal surface, which is of great value for monitoring disease activity. Additionally, the inability to biopsy and the potential risk of retention limit its value [17]. In contrast, double-balloon enteroscopy (DBE) is notably superior to CT and capsule endoscopy in the differential diagnosis of intraluminal small bowel diseases [18, 19].

Although there have been many studies reporting differential diagnosis of ISBCD, few of them are incorporating DBE analysis. Therefore, we thought that a systematic retrospective analysis including DBE of ISBCD and OSBUD was necessary.

2. Methods

2.1. Patients and Materials. All the procedures involving human participants were conducted in accordance with the standards of the Ethics Committee of the First Affiliated Hospital of Zhejiang University, the 1964 Declaration of Helsinki, and its later amendments or comparable ethical principles. Informed consent for the individual participant was waived since no patients were at risk in the retrospective analysis.

We collected data on patients who were hospitalized at the First Affiliated Hospital of Zhejiang University from January 01, 2013, to September 30, 2020, with small bowel ulcers detected by DBE. All patients completed a demographic survey before DBE and had it recorded in their medical records. Data included general information, medical history, physical examination, laboratory tests, radiology, DBE characteristics, and histology results. Smoking was defined as 5 or more cigarettes per day for more than 3 months, regardless of whether one was still currently smoking; alcohol consumption was defined as more than 140 g per week for men and more than 70 g per week for women for more than 3 months, regardless of whether one was still currently drinking. We recorded the location, number (1, or ≥2), morphology, depth, and concomitant manifestations of the ulcers of each patient as observed by DBE, and if an ulcer had multiple characteristics, each characteristic was recorded separately. Since there is still short of a clear definition of DBE ulcers, we drew on the definition of capsule endoscopic ulcers to generate classification in the supplementary material (available here) [20].

All patients underwent gastroscopy and colonoscopy within six months before the DBE examination. Laboratory tests and abdominal computed tomography scans were also performed within two weeks before the examination to rule out contraindications to DBE. Patients who underwent DBE review and patients who underwent DBE evaluation after small bowel transplantation were excluded. All patients (n = 275) with small bowel ulcers between the duodenum and ileum found by DBE were preliminarily included in the study. Then, patients with colonic and/or ileocecal valve lesions were excluded from the study (n = 45). Some patients were diagnosed by DBE pathological biopsy or postoperative pathology (n = 47); if it could not be confirmed by pathology, it would be confirmed according to the international diagnostic criteria of related diseases and the follow-up treatment effect. Therefore, all patients were followed up for at least 12 months. Patients whose final diagnosis were not determined (n = 29), including those with a diagnosis of nonspecific small bowel ulcer, were excluded. Finally, 139 patients with ISBCD and 62 patients with OSBUD were included in the study. The patients were divided into two groups, namely, ISBCD and OSBUD, according to their final diagnosis. The diagnosis and grouping process is detailed in Figure 1.

2.2. Statistics. The data were imported into SPSS 26.0 (IBM, Chicago, IL, USA) software for statistical analysis. The measurement data were first verified for normality using the Kolmogorov-Smirnov test. The data that conformed to a normal distribution are expressed as $\bar{x} \pm s$, and comparisons between groups were conducted using Student’s $t$-test. The data that did not conform to a normal distribution are expressed as the median and quartiles $M$ (Q1-Q3), and comparisons between groups were performed using the Mann-Whitney $U$ rank-sum test. The count data are expressed as $n$ and %. The $\chi^2$ test and Fisher’s exact test were used for comparisons between groups, and the Bonferroni method was used for intragroup analysis. All variables were evaluated as continuous predictors in univariate analysis. The variables with a higher odds ratio (OR) were added to a multiple logistic regression model to identify independent predictors for the presence of ISBCD. To identify candidate predictors of ISBCD, we performed a stepwise logistic regression analysis (probability to enter = 0.05 and probability to remove = 0.10). A simple model using representative variables was established to predict ISBCD based on the results of multiple logistic regression analyses. The goodness of fit of the models was evaluated using the Hosmer-Lemeshow statistic. The predictive accuracy of the models for detecting ISBCD was evaluated using areas under receiver-operating characteristic curves (AUROC) with 95% confidence intervals (CI). Sensitivities and specificities of the model were also calculated. A $p$ value less than 0.05 was considered statistically significant. Some data were calculated and plotted using GraphPad Prism 9 (GraphPad, San Diego, CA, USA).

3. Results

3.1. Etiological Classification. A total of 201 eligible patients with small bowel ulcers were enrolled. Of the total, ISBCD remained the main cause of small bowel ulcers in 139 patients (69.2%). There were 62 patients (30.8%) in OSBUD, including patients with lymphoma, diverticulum, cryptogenic multifocal ulcerous stenosing enteritis (CMUSE), drug-related ulcer, tuberculosis, ischemic enteropathy, eosinophilic enteritis, and polypl. The etiologies and locations of the ulcers are detailed in Table 1.
3.2. Demographics and Clinical Features. In ISBCD, the age of onset was 14 to 80 years, with a median of 37 (26–47) years. In OSBUD, the age of onset ranged from 20 to 80 years with a median of 48 (36–60) years. The age of onset was significantly different between the two groups ($p < 0.001$). To explore the difference, we divided the ages into the following six groups for analysis: $\leq 20$, 21–30, 31–40, 41–50, 51–60, and $\geq 61$ years. Between ISBCD and OSBUD, there were statistically significant differences in the $\leq 20$, 21–30, and $\geq 61$ year subgroups. There was no statistically significant difference in sex between the two groups ($p = 0.852$). In addition to drug-related ulcers (5 cases) in the traditional sense, 3 cases in ISBCD and 2 cases (small bowel adenocarcinoma and CMUSE) in OSBUD were also considered to be related to NSAIDs. This was because the patients developed new gastrointestinal bleeding on top of the original clinical symptoms after a period of NSAID use, and we believe that the drug use caused or promoted the development of ulcers. The proportion of patients who used nonsteroidal anti-inflammatory drugs (NSAIDs) for more than 2 weeks was higher in OSBUD (3 (2.2%) vs. 7 (11.3%), $p = 0.016$). Other general conditions were not significantly different between the two groups of patients.

Abdominal pain was the most common symptom, and it was observed significantly more frequently in ISBCD (117 (84.2%) vs. 32 (51.6%), $p < 0.001$). Diarrhea was more common in ISBCD (34 (24.5%) vs. 6 (9.7%), $p = 0.015$). A history of perianal lesions including severe hemorrhoids requiring surgical treatment, perianal abscesses, and anal fistulas was also more common in ISBCD (30 (21.6%) vs. 4 (6.5%), $p = 0.008$). Black stools (20 (14.4%) vs. 13 (35.5%), $p = 0.001$) and weakness (13 (9.4%) vs. 14 (22.6%), $p = 0.011$) were more common in OSBUD. The proportion of ISBCD patients with concomitant abdominal pain or

Figure 1: Diagnostic and grouping process. ISBCD: isolated small bowel Crohn’s disease; OSBUD: other small bowel ulcerative diseases.
diarrhea symptoms based on perianal lesions was significantly higher than that of OSBUD patients (22 (15.8%) vs. 2 (3.2%), \( p = 0.011 \)). Other clinical symptoms and extraintestinal manifestations were not significantly different between the two groups. Table 2 provides demographics and clinical features.

3.3. Laboratory Tests. Routine blood tests showed higher platelet counts and hemoglobin and hematocrit levels in ISBCD than in OSBUD (261 (215-330) vs. 231 (191-313), \( p = 0.037 \); 123 (106-138) vs. 107 (84-128), \( p < 0.001 \); 37.9% (34.2%-41.4%) vs. 33.6% (26.6%-39.2%), \( p < 0.001 \), respectively). Coagulation screening showed slightly higher fibrinogen levels in patients with ISBCD than in patients with OSBUD (3.11 (2.42-3.78) vs. 2.58 (2.15-3.32), \( p = 0.005 \)), but lower D-dimer levels than in the latter group (195 (170-459) vs. 411 (227-731), \( p < 0.001 \)). No significant differences were found between the two groups in terms of serum total calcium, lipid metabolism, inflammation, or tumor markers. Table 3 shows the comparisons of some of our laboratory tests.

3.4. Abdominal Computed Tomography. It was difficult to diagnose ulcers on the mucous surface by abdominal computed tomography. The data for only one patient in OSBUD suggested the presence of ulcer. The frequency of skip lesions in ISBCD was significantly higher than that in OSBUD (64 (46.0%) vs. 5 (8.1%), \( p < 0.001 \)). The proportion of ISBCD patients with bowel wall thickening was higher (122 (87.8%) vs. 34 (54.8%), \( p < 0.001 \)). There was no significant difference in the proportion of bowel strictures, intestinal wall enhancement, enhanced density of the perirectal fat, mesenteric lymph node enlargement, perforation, or mesenteric abscess between the two groups, as detailed in Table 4.

3.5. DBE Characteristics. The choice of the DBE approach was based on the patient’s clinical symptoms and other prior examination findings used to infer the location of the lesion, and if this could not be initially determined, both transoral and transanal examinations were performed. Of the 201 DBE examinations, 58 were transoral, 109 were transanal, and 34 were performed by both oral and anal approaches. The location of the ulcers was different between the two groups. Most of the ulcers in ISBCD occurred in the ileum (111 (79.9%)), while the proportion in the jejunum and ileum in OSBUD was similar (34 (54.8%) vs. 29 (46.8%)), and the probability of ulcer presence in the duodenum was lower in both groups (5 (3.6%) in ISBCD vs. 8 (12.9%) in OSBUD, \( p = 0.030 \)). Although the proportion of multifocal ulcers was higher in the ISBCD group as a whole (94 (67.6%) vs. 29 (46.8%), \( p = 0.005 \)), the proportion of

---

Table 1: Etiological classification and ulcer distribution of the 201 patients.

| Etiological classification | n (%) | Duodenum | Jejunum | Ileum |
|---------------------------|-------|----------|---------|-------|
| ISBCD                     | 139 (69.2) | 5 | 36 | 111 |
| OSBUD                     | 62 (30.8) | 8 | 34 | 29 |
| Lymphoma                  | 16 (8.0) | 0 | 10 | 7 |
| Diverticulum              | 5 (2.5) | 0 | 3 | 2 |
| Drug-related ulcer        | 5 (2.5) | 1 | 3 | 2 |
| CMUSE                     | 5 (2.5) | 0 | 3 | 4 |
| Stromal tumor             | 4 (2.0) | 1 | 3 | 0 |
| Tuberculosis              | 3 (1.5) | 0 | 0 | 3 |
| Eosinophilic enteritis    | 3 (1.5) | 1 | 3 | 2 |
| Adenocarcinoma            | 3 (1.5) | 1 | 3 | 0 |
| Henoch-Schönlein purpura | 3 (1.5) | 2 | 2 | 0 |
| Behcet’s disease          | 2 (1.0) | 0 | 0 | 2 |
| Ischemic bowel disease    | 2 (1.0) | 0 | 0 | 2 |
| Neuroendocrine carcinoma  | 2 (1.0) | 0 | 2 | 0 |
| Polyp                     | 2 (1.0) | 0 | 2 | 0 |
| Inflammatory granuloma    | 2 (1.0) | 0 | 0 | 2 |
| Poorly differentiated carcinoma | 1 (0.5) | 1 | 0 | 0 |
| Multiple myeloma          | 1 (0.5) | 0 | 0 | 1 |
| Parasite infection        | 1 (0.5) | 1 | 0 | 0 |
| Lipoma                    | 1 (0.5) | 0 | 0 | 1 |
| Duplication of small intestine | 1 (0.5) | 0 | 0 | 1 |
| Total                     | 201 (100.0) | 13 | 70 | 140 |

ISBCD: isolated small bowel Crohn’s disease; OSBUD: other small bowel ulcerative diseases; CMUSE: cryptogenic multifocal ulcerous stenosing enteritis.
Table 2: Demographic and clinical features of ISBCD and OSBUD patients.

| Characteristics                       | ISBCD        | OSBUD       | p value |
|---------------------------------------|--------------|-------------|---------|
|                                       | n (%) or median/mean | n (%) or median/mean |         |
| **Demographics**                     |              |             |         |
| Age (years, median)                   | 37 (26–47)   | 48 (36–60)  | <0.001  |
| ≤20                                   | 20 (14.4)ª   | 1 (1.6)ª    |         |
| 21-30                                 | 35 (25.2)ª   | 8 (12.9)ª   |         |
| 31-40                                 | 31 (22.3)ª   | 11 (17.7)ª  |         |
| 40-50                                 | 24 (17.3)ª   | 16 (25.8)ª  |         |
| 51-60                                 | 18 (12.9)ª   | 11 (17.7)ª  |         |
| ≥61                                   | 11 (7.9)ª    | 15 (24.2)ª  |         |
| Sex (male, n (%))                     | 96 (69.1)    | 42 (67.7)   | 0.852   |
| Disease duration (months, median)     | 12.0 (2.0-36.0) | 6.0 (1.8-24.0) | 0.183   |
| Medication history of NSAIDs for more than two weeks (n (%)) | 3 (2.2) | 7 (11.3) | 0.016 |
| BMI (kg/m², median)                   | 20.52 (19.03-22.84) | 21.30 (19.05-23.59) | 0.145 |
| **Education level**                   |              |             |         |
| Illiteracy                            | 8 (5.8)      | 0 (0)       |         |
| Primary education                     | 99 (71.2)    | 51 (82.3)   | 0.221   |
| Higher education                      | 32 (23.0)    | 11 (17.7)   |         |
| History of tumor in immediate family  | 14 (10.1)    | 10 (16.1)   |         |
| Smoking                               | 39 (28.1)    | 19 (30.6)   | 0.708   |
| Drinking                              | 19 (13.7)    | 5 (8.1)     | 0.258   |
| Blood type                            |              |             | 0.347   |
| A                                     | 48 (34.5)    | 16 (25.8)   |         |
| B                                     | 40 (28.8)    | 17 (27.4)   |         |
| O                                     | 37 (26.6)    | 24 (38.7)   |         |
| AB                                    | 14 (10.1)    | 5 (8.1)     |         |
| History of perianal lesion (n %)      | 30 (21.6)    | 4 (6.5)     | 0.008   |
| History of appendectomy (n %)         | 16 (11.5)    | 3 (4.8)     | 0.135   |
| General symptoms (n %)                |              |             |         |
| Fever                                 | 15 (10.8)    | 5 (8.1)     | 0.551   |
| Weakness                              | 13 (9.4)     | 14 (22.6)   | 0.011   |
| Weight loss                           | 47 (33.8)    | 17 (27.4)   | 0.369   |
| Gastrointestinal symptoms (n %)       |              |             |         |
| Abdominal pain                        | 117 (84.2)   | 32 (51.6)   | <0.001  |
| Diarrhea                              | 34 (24.5%)   | 6 (9.7)     | 0.015   |
| Black stool                           | 20 (14.4)    | 13 (35.5)   | 0.001   |
| Nausea and vomiting                   | 44 (31.7)    | 14 (22.6)   | 0.190   |
| Abdominal distention                  | 31 (22.3)    | 13 (21.0)   | 0.833   |
| Bloody stool                          | 17 (12.2)    | 5 (8.1)     | 0.382   |
| Ileus                                 | 11 (7.9)     | 2 (3.2)     | 0.348   |
| Mucous stool                          | 5 (3.6)      | 1 (1.6)     | 0.753   |
| Abdominal mass                        | 4 (2.9)      | 0 (0)       | 0.422   |
| Abdominal discomfort                  | 3 (2.2)      | 0 (0)       | 0.554   |
multiple intestinal segments involved in the two groups was similar (11 (7.9%) vs. 7 (11.3%), p = 0.439). ISBCD differed in the terms of the morphology of major ulcers in different intestinal segments. The probability that the majority of ulcers were superficial small ulcers (3 (60.0%) vs. 18 (51.4%) vs. 20 (17.9%), p < 0.001) and longitudinal ulcers (0 (0%) vs. 5 (14.3%) vs. 65 (58.0%), p < 0.001) was different in the duodenum, jejunum, and ileum. In contrast, the main ulcer morphology in OSBUD was similar in different intestinal segments, with superficial small ulcers (5 (62.5%) vs. 17 (50.0%) vs. 15 (51.7%), p = 0.813), longitudinal ulcers (0 (0%) vs. 3 (8.8%) vs. 1 (3.4%), p = 0.766), and large ulcers (1 (21.5%) vs. 9 (26.5%) vs. 5 (17.2%), p = 0.541). Further analysis of the 18 patients with multiple bowel segments affected showed no significant difference in the proportion of inconsistent ulcer morphologies in different bowel segments in the same patient (9 (81.8%) vs. 5 (71.4%), p = 1.000).

Through the analysis of the morphology and concomitant endoscopic features of ulcers in different intestinal segments, we found the following characteristics:

1. The main morphology of ulcers in ISBCD was different in different intestinal segments, but there was no significant difference in OSBUD

2. Longitudinal ulcers in the ileum could help to identify ISBCD, but ulcers in the jejunum did not have good differential significance. No longitudinal ulcers in the duodenum were found in this study

3. Only in the jejunum, ulcers with intestinal stenosis were more likely to be ISBCD (17 (47.2%) vs. 7 (20.6%), p = 0.019)

4. At the individual level, the morphology of major ulcers varied from one intestinal segment to another in the same patient

5. Ulcers accompanied by mucosal hyperplasia were not the typical manifestation of ISBCD

Tables 5 and 6 show the mode of entry, ulcer location, characteristics, and concomitant manifestations observed.

### Table 2: Continued.

| Characteristics | ISBCD (n (%) or median/mean) | OSBUD (n (%) or median/mean) | p value |
|-----------------|-----------------------------|-----------------------------|---------|
| Oral ulcers     | 44 (31.7)                  | 13 (21.0)                  | 0.121   |
| Genital ulcers  | 6 (4.3)                     | 4 (6.5)                     | 0.770   |
| Joint pain      | 25 (18.0)                   | 10 (16.1)                   | 0.749   |
| Skin lesions    | 11 (7.9)                    | 5 (8.1)                     | 1.000   |
| Episcleritis    | 6 (4.3)                     | 1 (1.6)                     | 0.583   |

### Table 3: Laboratory tests.

| Items                          | ISBCD (n = 139) | OSBUD (n = 62) | p value |
|-------------------------------|-----------------|----------------|---------|
| Hemoglobin (g/L)              | 123 (106-138)   | 107 (84-128)   | <0.001  |
| Hematocrit (%)                | 37.9 (34.2-41.4)| 33.6 (26.6-39.2)|<0.001  |
| D-dimer (μg/L)                | 195 (170-459)  | 411 (227-731)  | <0.001  |
| Fibrinogen (g/L)              | 3.11 (2.4-3.78) | 2.58 (2.15-3.32)|0.005    |
| Platelet count (×10^9/L)      | 261 (215-330)  | 231 (191-313)  | 0.037   |
| White blood cell count (×10^9/L)| 5.2 (4.3-6.5) | 5.3 (3.8-6.6)  | 0.616   |
| Neutrophil ratio (%)          | 64.0 ± 0.9      | 64.0 ± 1.5     | 0.985   |
| Lymphocyte ratio (%)          | 25.4 ± 0.8      | 25.0 ± 1.3     | 0.752   |
| Mean corpuscular volume (fl)  | 86.8 (84.2-92.4)| 85.8 (82.4-90.4)|0.179   |
| Total calcium (mmol/L)        | 2.15 ± 0.01     | 2.12 ± 0.02    | 0.088   |
| Uric acid (μmol/L)            | 297 (239-359)  | 300 (236-351)  | 0.691   |
| Albumin (g/L)                 | 39.2 ± 0.5      | 38.7 ± 0.7     | 0.540   |
| Total cholesterol (mmol/L)    | 3.56 (3.02-4.00)| 3.65 (3.22-4.08)|0.526   |
| Triglycerides (mmol/L)        | 0.97 (0.76-1.38)| 1.04 (0.82-1.38)|0.576   |
| CEA (ng/mL)                   | 1.3 (0.9-1.9)   | 1.6 (1.0-2.3)  | 0.067   |
| CRP (mg/L)                    | 3.80 (1.26-16.0)| 1.60 (0.55-19.70)|0.165   |
| ESR (mm/60 min)               | 10 (6-20)       | 8 (3-19)       | 0.273   |
| Ferritin (ng/mL)              | 52.2 (14.1-148.3)| 60.7 (11.1-195.8)|0.731   |

CEA: carcinoembryonic antigen; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.
by DBE. Figure 2 shows the manifestation and histopathology of ISBCD patients observed by DBE. Figure 3 shows the manifestation of patients with some OSBUD as observed by DBE.

### 3.6. Pathological Histology

Pathological biopsies were collected from 127 patients (91.4%) in ISBCD and 54 patients (87.1%) in OSBUD. There was no significant difference in the proportion of biopsies collected from the two groups ($p = 0.350$). Nonnecrotic granulomas were present in 14 cases of ISBCD (13 from pathology obtained by DBE and 1 postoperative pathology) and in a case of OSBUD (patient with multiple myeloma). Although we usually consider nonnecrotic granulomas as a characteristic pathological manifestation of CD, no statistical difference was reflected between the two in our study (14 (10.1%) vs. 1 (1.6%), $p = 0.069$). Pathological histology suggested a diagnosis in a total of 11 (7.9%) patients in ISBCD and 12 (19.4%) patients in OSBUD ($p = 0.019$). Considering the improvement of pathological diagnosis technology, we further analyzed the

### Table 4: Abdominal computed tomography.

| Characteristics                                      | ISBCD (n (%)) | OSBUD (n (%)) | p value |
|------------------------------------------------------|---------------|---------------|---------|
| Skip lesions                                         | 64 (46.0)     | 5 (8.1)       | <0.001  |
| Bowel wall thickening                                | 122 (87.8)    | 34 (54.8)     | <0.001  |
| Bowel strictures                                      | 44 (31.7)     | 19 (20.6)     | 0.887   |
| Mural hyperenhancement                                | 29 (20.9)     | 14 (22.6)     | 0.784   |
| Ulcers                                               | 0 (0)         | 1 (1.6)       | 0.308   |
| Enhanced density of the peri-intestinal fat           | 11 (7.9)      | 5 (8.1)       | 1.000   |
| Enlarged lymph nodes                                  | 41 (29.5)     | 23 (37.1)     | 0.285   |
| Fistula                                               | 7 (5.0)       | 0 (0)         | 0.167   |
| Perforation                                           | 2 (1.4)       | 0 (0)         | 1.000   |
| Abscess                                               | 2 (1.4)       | 0 (0)         | 1.000   |

### Table 5: Entry mode and ulcer distribution.

| Entry mode                                      | ISBCD (n (%)) | OSBUD (%) | p value |
|-------------------------------------------------|---------------|-----------|---------|
| Transoral                                       | 22 (15.8)$^a$| 36 (58.1)$^b$| <0.001  |
| Transanal                                       | 92 (66.2)$^a$| 17 (27.4)$^b$|         |
| Both oral and anal                              | 25 (18.0)$^a$| 9 (14.5)$^a$|         |
| Duodenum                                        | 5 (3.6)       | 8 (12.9)   | 0.030   |
| Jejunum                                         | 36 (25.9)     | 34 (54.8)  | <0.001  |
| Ileum                                           | 111 (79.9)    | 29 (46.8)  | <0.001  |
| Multifocal ulcer                                | 94 (67.6)     | 29 (46.8)  | 0.005   |
| Multiple intestinal segments involved           | 11 (7.9)      | 7 (11.3)   | 0.439   |

$^a$ and $^b$ are the subgroups that differed by Bonferroni correction.

### Table 6: Characteristics of ulcers in different intestinal segments.

| Characteristics | Duodenum (n (%)) | Jejunum (n (%)) | Ileum (n (%)) | p value | Duodenum (n (%)) | Jejunum (n (%)) | Ileum (n (%)) | p value | Duodenum (n (%)) | Jejunum (n (%)) | Ileum (n (%)) | p value |
|-----------------|------------------|-----------------|--------------|---------|------------------|-----------------|--------------|---------|------------------|-----------------|--------------|---------|
| Longitudinal ulcer | 0 (0)            | 0 (0)           | —            |         | 5 (13.9)         | 3 (8.8)         | 0.772        |         | 65 (58.6)        | 1 (1.5)         | <0.001       |
| Superficial small ulcer | 3 (60.0)        | 5 (62.5)        | 1.000        |         | 18 (50.0)        | 17 (50.0)       | 1.000        |         | 20 (18.0)        | 15 (51.7)       | <0.001       |
| Large ulcer      | 0 (0)            | 1 (12.5)        | 1.000        |         | 0 (0)            | 9 (26.5)        | 0.003        |         | 5 (4.5)          | 5 (17.2)        | 0.049        |
| Circular ulcer   | 0 (0)            | 0 (0)           | —            |         | 6 (16.7)         | 5 (14.7)        | 0.822        |         | 17 (15.3)        | 8 (27.6)        | 0.124        |
| Irregular ulcer  | 0 (0)            | 0 (0)           | —            |         | 3 (8.3)          | 0 (0)           | 0.258        |         | 6 (5.4)          | 3 (10.3)        | 0.589        |
| Ulcer scar       | 0 (0)            | 1 (12.5)        | 1.000        |         | 7 (19.4)         | 1 (2.9)         | 0.073        |         | 11 (9.9)         | 0 (0)           | 0.168        |
| Linear ulcer     | 2 (40.0)         | 0 (0)           | 0.128        |         | 0 (0)            | 1 (2.9)         | 0.486        |         | 6 (5.4)          | 1 (3.4)         | 1.000        |
| Deep ulcer       | 0 (0)            | 1 (12.5)        | 1.000        |         | 0 (0)            | 4 (11.8)        | 0.109        |         | 2 (1.8)          | 0 (0)           | 1.000        |
| Intestinal stenosis | 0 (0)           | 0 (0)           | —            |         | 17 (47.2)        | 7 (20.6)        | 0.019        |         | 50 (45.0)        | 11 (37.9)       | 0.491        |
| Mucosal hyperplasia | 0 (0)            | 0 (0)           | —            |         | 5 (13.9)         | 2 (5.9)         | 0.473        |         | 28 (25.2)        | 4 (13.8)        | 0.192        |
3.7. Derivation of the ISBCD Diagnostic Model. Univariate analysis showed that age of onset, clinical features (abdominal pain, diarrhea, weakness, black stool, history of perianal lesion, medication history of NSAIDs for more than two weeks), laboratory tests (hemoglobin, hematocrit, fibrinogen, D-dimer), abdominal computed tomography (skip lesions, bowel wall thickening), and DBE characteristics (ulcer location, superficial small ulcer, longitudinal ulcer, large ulcer, multifocal ulcer, intestinal stenosis) were significantly different between ISBCD and OSBUD. Among these variables, significant interactions were found between diarrhea, weakness, black stool, history of perianal lesion, hemoglobin, hematocrit, bowel wall thickening, ulcer location, superficial small ulcer, multifocal ulcer, and intestinal stenosis. To avoid these interactions, we incorporated representative variables with the highest ORs into the multivariate analysis. Finally, we utilized age of onset, abdominal pain, medication history of NSAIDs for more than two weeks, fibrinogen, D-dimer, skip lesions, longitudinal ulcer, and large ulcer for the multivariate analysis.

The multivariate analysis showed that age of onset (OR: 0.968, 95% CI: 0.942-0.995; \( p = 0.020 \)), abdominal pain (OR: 3.455, 95% CI: 1.394-8.564; \( p = 0.072 \)), medication history of NSAIDs for more than two weeks (OR: 0.087, 95% CI: 0.006-1.248; \( p = 0.072 \)), fibrinogen (OR: 1.594, 95% CI:...
0.957-2.655; \( p = 0.074 \), D-dimer (OR: 0.999, 95% CI: 0.999-1.000; \( p = 0.044 \)), skip lesions (OR: 7.254, 95% CI: 2.211-23.795; \( p = 0.001 \)), longitudinal ulcer (OR: 8.706, 95% CI: 2.360-32.120; \( p = 0.001 \)), and large ulcer (OR: 0.194, 95% CI: 0.043-0.871; \( p = 0.032 \)) were independent risk factors for ISBCD after adjusting for interactions between variables (Table 7). In this binary logistic regression model, the probability of having ISBCD was \( \frac{1}{1 + e^{0.358 + \text{age} \times 0.032 - \text{abdominal pain} \times 1.240 + \text{NSAIDs used more than two weeks} \times 2.439 - \text{skip lesions} \times 1.982 - \text{fibrinogen} \times 0.466 + \text{D-dimer} \times 0.001 \text{--longitudinal ulcer} \times 2.164 + \text{large ulcer} \times 1.640} \). We utilized the exponent of this formula and changed the multiplicative factors into the corresponding magnification coefficient. We call this formula the ISBCD index as follows: ISBCD index = abdominal pain (1, if yes) \times 30 – age of onset – medication history of NSAIDs more than two weeks (1, if yes) \times 10 + skip lesions (1, if yes) \times 70 + fibrinogen (g/L) \times 20 – D-dimer (\mu g/L)/10 + longitudinal ulcer (1, if yes) \times 80 – large ulcer (1, if yes) \times 10.

Figure 3: Double-balloon enteroscopy of patients with some other small bowel ulcerative diseases. (a) Cryptogenic multifocal ulcerous stenosing enteritis showed circular ulcer with luminal stenosis. (b) Behcet’s disease. (c) Lymphoma. (d) Eosinophilic enteritis. (e) Adenocarcinoma with ulcers, strictures, and capsule endoscopic retention. (f) Diverticulum with ulcer. (g) Inflammatory granuloma with ulcer. (h) Drug (NSAID)-related ulcer (the mucosa was pale due to severe anemia.).
The AUROC of the original formula was 0.903 (95% CI: 0.861-0.946), and the AUROC of the ISBCD index was 0.877 (95% CI: 0.830-0.925) (Figure 5). The diagnosis of ISBCD was more likely if the values were higher than the cut-off value 30.2 (Youden index = 0.642, sensitivity 75.5%, specificity 88.7%, positive likelihood ratio 6.68, negative likelihood ratio 0.28).

4. Discussion

Small bowel ulcers exist in many kinds of small bowel diseases. The proportion of complications increases as the disease progresses. As a result, early diagnosis is particularly important [21]. In our study, OSBUD is a collection of multiple diseases, because of the low prevalence of ulcerative disease of the small intestine and the fewer cases of related diseases, which is not sufficient for statistically significant subgroup analysis. But as the distribution of ulcers listed in Table 1, OSBUD still has similar commonalities in the distribution of ulcers. Two cases of polyps and one case of lipoma were included in OSBUD because the ulceration at the lesion resulted in not the typical polyp and lipoma presentation on DBE but rather mucosal hyperplasia-like changes, such that they were mistaken for mucosal hyperplasia due to ulceration at the initial diagnosis, but the final pathological biopsy confirmed polyps and lipoma. ISBCD (median age 37 years) was younger than OSBUD (median age 48 years). The proportion of patients with ISBCD was significantly higher among those with an age of onset of 30 years and younger. NG et al. found two peaks in the age of onset of CD, 20–24 years and 40–44 years [1]. However, in our study, we found no significant difference between the two groups in terms of the proportion of patients in the second peak interval (40–50 years). From the perspective of real-world clinical differentiation, age ≤ 30 years may be of more practical value as a diagnostic basis for ISBCD in the cluster of isolated small bowel ulcerative disease.

The symptoms of CD are heterogeneous but commonly include abdominal pain, weight loss, and chronic diarrhea [22]. A retrospective study carried out at Seoul National University Hospital observed that 41% of patients with Crohn’s disease had coexisting perianal lesions [23]. In our study, there were significant differences in certain symptoms between the two groups, but it remains difficult in practice to distinguish between the two groups based on a single clinical symptom. The use of NSAIDs drugs is thought to be associated with small bowel ulcers [24]. This is further confirmed by the fact that three ISBCD and seven OSBUD patients in our study developed symptoms of gastrointestinal bleeding after more than two weeks of NSAIDs drug use.

In our study, the overall hemoglobin and hematocrit levels in ISBCD were significantly higher than those in OSBUD. Another study concluded that anemia was associated with the risk of CD [25]. Compared with our study, that study focused on the difference in data between CD patients and the general population. In patients with established small bowel ulcers, anemia may be observed more often in patients with other small bowel diseases than in patients with ISBCD. This finding is consistent with the fact that OSBUD in this study was more likely to have clinical symptoms with black stools and fatigue.

Collins et al. demonstrated that in patients with inflammatory bowel disease (IBD), platelets circulate through the mesenteric microcirculation in a highly activated state [26, 27]. During inflammatory activation, platelets induce the expression of some chemokines, complement components, and receptors for cytokines that together participate in various inflammatory responses in inflammatory bowel disease [28]. Harries et al. also noted in their study that platelet counts were significantly higher in patients with IBD than in patients with infectious diarrhea [29]. In our study, we also found higher platelet count levels in ISBCD with small bowel ulcers than in OSBUD. This finding is consistent with Li et al. [30]. Although our median platelet count level of 268 × 10^9/L was lower than their reported level of 294.58 × 10^9/L, this difference may be related to the selection of a specific CD population in our study.

C-reactive protein (CRP) levels have been reported to be elevated in patients with CD and to correlate with disease activity, making it a commonly used marker to assess the degree of CD activity [31, 32]. The white blood cell count, serum albumin level, and erythrocyte sedimentation rate (ESR) are commonly used indicators to reflect the nutritional status and inflammation of the body. These measures have a certain auxiliary value for the diagnosis of diseases [33, 34]. However, in our study, the differences in these indicators were not significant between the two groups of patients. This finding may be related to our choice of the diseased group as a control.

The coagulation system is an important component of the pathogenesis of IBD [35]. In our study, we found differences in fibrinogen and D-dimer between the two groups of patients. This also suggests that it is necessary to make coagulation screening a routine test for admission of CD patients. We chose these serum biomarkers for comparison and analysis because they are commonly and inexpensively detected in clinical practice.

ISBCD has DBE characteristics that distinguish it from OSBUD. In our study, both longitudinal ulcers occurring in the ileum and luminal strictures occurring in the jejunum.
were more likely to be found in ISBCD patients. Keuchel et al. highlighted many studies that used capsule endoscopy for the diagnosis of ulcerative disease of the small intestine and stated in their article that it is inappropriate to determine small bowel disease by the morphology of the ulcer. We remain skeptical of this argument because we believe that capsule endoscopy has limitations in the observation of ulcer morphology, especially in the holistic view (limited by the degree of intestinal lumen filling during capsule passage, interference of air bubbles and chyme, and propulsive peristalsis of the intestinal lumen), while DBE overcomes this difficulty. Therefore, it is very meaningful to identify ISBCD by summarizing the distribution, morphology, and concomitant manifestations of ulcers under DBE.

The major ulcer morphology in patients with ISBCD is different in different small bowel segments. Even at the individual patient level when multiple small bowel segments are involved, in most cases, the ulcer morphology is also different in different bowel segments. As mentioned by Coelho-Prabhu and Kane and Atreya and Siegmund in their respective articles, location played a very important role in Crohn’s disease, both in terms of disease classification and in prognostic assessments [36, 37]. We believe that this characteristic is also present in ISBCD. Ulcer morphology, as an external reflection, not only is related to the type of disease but also may be related to the intestinal segment in which the ulcer is located. The reasons and mechanisms may be related to factors such as the physiological function and flora distribution of different small intestinal segments and need to be confirmed by more in-depth studies.

DBE can provide access to biopsy tissue, which can sometimes provide a critical basis for disease identification. However, we also need to realize that the pathological tissue obtained by DBE is small and superficial. ISBCD, a disease with a tendency to transmural inflammation, is often difficult to diagnose by DBE biopsies. However, this does not mean that DBE biopsy is not significant, as it is still of great interest in the differentiation of ISBCD from other diseases, such as lymphoma, intestinal tuberculosis, and adenocarcinoma [38–40]. As in our studies in 2014 and 2015, the use of DBE biopsy to obtain pathological tissue could directly diagnose 50% of OSBUD, which was difficult to do with other tests.

Considering that the diagnosis of ISBCD is difficult to determine by a specific characteristic or indicator, and to the best of our knowledge, there is no diagnostic model of ISBCD that includes DBE. We performed a multifactorial binary logistic regression analysis of the differential variables between the two groups of patients and finally derived the ISBCD index as a diagnostic model, which has positive implications for the diagnosis of ISBCD.

### 5. Conclusion

In summary, clinical features, laboratory tests, and abdominal computed tomography can all provide a basis for the diagnosis of ISBCD. DBE, as a powerful tool that allows clear and direct visualization of the mucosal surface of the small intestine, can provide very important information for the diagnosis and differential diagnosis of ISBCD. Our conclusions from this single-center retrospective study have some limitations and the possibility of bias, so a multicenter, large sample study on the ulcerative characteristics of ISBCD observed by DBE is necessary.

### Abbreviations

ISBCD: Isolated small bowel Crohn’s disease
DBE: Double-balloon enteroscopy
OSBUD: Other small bowel ulcerative diseases
CD: Crohn’s disease
CMUSE: Cryptogenic multifocal ulcerous stenosing enteritis
CT: Computed tomography
IBD: Inflammatory bowel disease
CEA: Carcinoembryonic antigen
CRP: C-reactive protein
ESR: Erythrocyte sedimentation rate
CI: Confidence interval.

Data Availability

All the data can be found in this manuscript or received from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Study design and data analysis were contributed by Meng Niu and Chun-xiao Chen. Data collection and writing of the first draft of the paper were contributed by Meng Niu, Zheng-hao Chen, and Xing Zhang. Formal writing, reviewing, and editing of the manuscript were contributed by Meng Niu, Meng Li, and Chun-xiao Chen.

Supplementary Materials

we drew on the definition of capsule endoscopic ulcers to generate classification in the supplementary material. (Supplementary Materials)

References

[1] S. C. Ng, W. Tang, J. Y. Ching et al., ”Incidence and phenotype of inflammatory bowel disease based on results from the Asia-Pacific Crohn’s and colitis epidemiology study,” Gastroenterology, vol. 145, no. 1, pp. 158–165.e2, 2013.
[2] J. Satsangi, M. S. Silverberg, S. Vermeire, and J. F. Colombel, ”The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications,” Gut, vol. 55, no. 6, pp. 749–753, 2006.
[3] B. Hall, G. Holleran, and D. McNamara,”Small bowel Crohn’s disease: an emerging disease phenotype?,” Digestive Diseases, vol. 33, no. 1, pp. 42–51, 2015.
[4] M. Esaki, T. Matsumoto, N. Ohmiya et al., ”Capsule endoscopy findings for the diagnosis of Crohn’s disease: a nationwide case-control study,” Journal of Gastroenterology, vol. 54, no. 3, pp. 249–260, 2019.
[5] F. F. Wu, Q. Xie, X. S. Huang et al., ”Endoscopic features and clinical characteristics of ulcerations with isolated involvement of the small bowel,” The Turkish Journal of Gastroenterology, vol. 32, no. 4, pp. 401–411, 2021.
[6] N. Xu, Z. Yu, X. Cao, Z. Wang, and M. Yan, ”Characteristics of nonsteroidal anti-inflammatory drugs (NSAIDs)-induced small bowel injury identified by single-balloon endoscopy or capsule endoscopy,” Medical Science Monitor, vol. 23, pp. 5237–5245, 2017.
[7] M. Saitou, D. Nemoto, K. Utano et al., ”Identification of intestinal abnormalities in patients with active pulmonary tuberculosis using small bowel capsule endoscopy,” Endoscopy International Open, vol. 6, no. 9, pp. E1103–E1108, 2018.
[8] Z. Wang, W. Zhang, C. Luo et al., ”Primary intestinal Epstein-Barr virus-associated natural killer/T-cell lymphoproliferative disorder: a disease mimicking inflammatory bowel disease,” Journal of Crohn’s and Colitis, vol. 12, no. 8, pp. 896–904, 2018.
[9] Y. N. Wang, J. Li, Y. H. Ni et al., ”The clinical characteristics of patients with monomorphic epitheliotropic intestinal T-cell lymphoma characterized by minor endoscopic abnormalities,” Zhonghua Wei Chao Wei Bing Za Zhi, vol. 57, no. 2, pp. 112–117, 2018.
[10] J. Arimoto, H. Endo, T. Kato et al., ”Clinical value of capsule endoscopy for detecting small bowel lesions in patients with intestinal Behçet’s disease,” Digestive Endoscopy, vol. 28, no. 2, pp. 179–185, 2016.
[11] Y. Ohnuki, Y. Moriya, S. Yutani et al., ”Eosinophilic granulomatosis with polyangitis (Churg-Strauss syndrome) complicated by perforation of the small intestine and cholecystitis,” Internal Medicine, vol. 57, no. 5, pp. 737–740, 2018.
[12] D. García-Compeán, A. R. Jiménez-Rodríguez, A. N. Del Cueto-Águilera, G. Herrera-Quíones, J. A. González-González, and H. J. Maldonado-Garza, ”Mecckel’s diverticulism diagnosis by video capsule endoscopy: a case report and review of literature,” World Journal of Clinical Cases, vol. 6, no. 14, pp. 791–799, 2018.
[13] W. S. Jeong, H. J. Song, S. Y. Na et al., ”Acute extensive ischemic enteritis in a young man diagnosed with wireless capsule endoscopy: a case report,” The Korean Journal of Gastroenterology, vol. 61, no. 3, p. 160, 2013.
[14] M. Keuchel, N. Kurniawan, and P. Baltes, ”Small bowel ulcers,” Current Opinion in Gastroenterology, vol. 35, no. 3, pp. 213–222, 2019.
[15] J. Rimola, N. Planell, S. Rodríguez et al., ”Charactetization of inflammation and fibrosis in Crohn’s disease lesions by magnetic resonance imaging,” American Journal of Gastroenterology, vol. 110, no. 3, pp. 432–440, 2015.
[16] Y. Qiu, R. Mao, B.-L. Chen et al., ”Systematic review with meta-analysis: magnetic resonance enterography vs. computed tomography enterography for evaluating disease activity in small bowel Crohn’s disease,” Journal of Clinical Gastroenterology, vol. 51, no. 10, pp. E1103–E1108, 2018.
[17] M. Nishimura, T. Kato, and K. Endo, ”Clinical significance of multi-detector CT enterography for evaluating disease activity in small bowel Crohn’s disease,” Gastroenterology Research and Practice, vol. 2016, Article ID 5172873, 6 pages, 2016.
[18] R. Leenhardt, A. Buisson, A. Bourrelle et al., ”Nomenclature and semantic descriptions of ulcerative and inflammatory lesions seen in Crohn’s disease in small bowel capsule endoscopy: an international Delphi consensus statement,” United European Gastroenterology Journal, vol. 8, no. 1, pp. 99–107, 2020.
[21] K. S. de Barros, C. Flores, L. Harlacher, and C. F. Francescon, “Evolution of clinical behavior in Crohn’s disease: factors associated with complicated disease and surgery,” *Digestive Diseases and Sciences*, vol. 62, no. 9, pp. 2481–2488, 2017.

[22] F. Gomollón, A. Dignass, V. Annese et al., “3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management,” *Journal of Crohn’s and Colitis*, vol. 11, no. 1, pp. 3–25, 2017.

[23] H. D. Kim, C. G. Kim, J. W. Kim et al., “Clinical features and therapeutic responses of perianal lesions in Crohn’s disease,” *The Korean Journal of Gastroenterology*, vol. 42, no. 2, pp. 128–133, 2003.

[24] Y. J. Lim and C.-H. Yang, “Non-steroidal anti-inflammatory drug-induced enteropathy,” *Clinical Endoscopy*, vol. 45, no. 2, pp. 138–144, 2012.

[25] E. A. Kang, J. Chun, J. P. Im et al., “Anemia is associated with the risk of Crohn’s disease, not ulcerative colitis: a nationwide population-based cohort study,” *PLoS One*, vol. 15, no. 9, article e0238244, 2020.

[26] C. E. Collins, M. R. Cahill, A.-C. Newland, and D. S. Rampton, “Platelets circulate in an activated state in inflammatory bowel disease,” *Gastroenterology*, vol. 106, no. 4, pp. 840–845, 1994.

[27] C. E. Collins, D. S. Rampton, J. Rogers, and N. S. Williams, “Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease,” *European Journal of Gastroenterology & Hepatology*, vol. 9, no. 12, pp. 1213–1217, 1997.

[28] E. Voudoukis, K. Karmiris, and I. E. Koutroubakis, “Multipotent role of platelets in inflammatory bowel disease: a clinical approach,” *World Journal of Gastroenterology*, vol. 20, no. 12, pp. 3180–3190, 2014.

[29] A. D. Harries, N. J. Beeching, S. J. Rogerson, and F. J. Nye, “The platelet count as a simple measure to distinguish inflammatory bowel disease from infective diarrhoea,” *Journal of Infection*, vol. 22, no. 3, pp. 247–250, 1991.

[30] L. Li, P. Xu, Z. Zhang, X. Zhou, C. Chen, and C. Lu, “Platelets can reflect the severity of Crohn’s disease without the effect of anemia,” *Clinics*, vol. 75, article e1596, 2020.

[31] J.-M. Benitez, M.-A. Meuwis, C. Reinaers, C. van Kemseke, P. Meunier, and E. Louis, “Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring,” *Gut*, vol. 62, no. 12, pp. 1806–1816, 2013.

[32] C. Ma, R. Battat, C. E. Parker, R. Khanna, V. Jairath, and B. G. Feagan, “Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease?,” *Expert Review of Gastroenterology & Hepatology*, vol. 13, no. 4, pp. 319–330, 2019.

[33] U. Daniluk, J. Daniluk, M. Krasnodebska, J. M. Lotowska, M. E. Sobaniec-Lotowska, and D. M. Lebenschtejn, “The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn’s disease,” *Advances in Medical Sciences*, vol. 64, no. 1, pp. 9–14, 2019.

[34] G. R. Lichtenstein, E. V. Loftus, K. L. Isaacs, M. D. Regueiro, L. B. Gerson, and B. E. Sands, “ACG clinical guideline: management of Crohn’s disease in adults,” *American Journal of Gastroenterology*, vol. 113, no. 4, pp. 481–517, 2018.

[35] S. Danese, A. Papa, S. Saibeni, A. Repici, A. Malesci, and M. Vecchi, “Inflammation and coagulation in inflammatory bowel disease: the clot thickens,” *The American Journal of Gastroenterology*, vol. 102, no. 1, pp. 174–186, 2007.